Search results (17)
« Back to NewsVacancy: Senior Postdoctoral Scientist - Tumour Immunology
7 April 2025
Research Grade 8: £48,235 - £57,255 with a discretionary range to £64,228 p.a. (pro rata). This is inclusive of a pensionable Oxford University Weighting of £1,500 per year (pro rata).
Cancer vaccination uncovers novel characteristics of a well-known tumour antigen and mediates anti tumour immunity in new settings
9 October 2024
The Van den Eynde group identify a new CD8+ T-cell epitope of the MAGE-type P1A tumour antigen presented in a widely-used tumour model, opening new perspectives for mechanistic studies looking at MAGE-type specific anti-tumour immunity.
Adoptive T cell therapy with PHD2/3-deficient CD8 T cells shows an enhanced tumour response
6 September 2024
The Van den Eynde group demonstrate that deletion of PHD2/3 enzymes in CD8 T cells show an enhanced tumour response in various cancer models
Ludwig Oxford and IDRM host 6th form students for a taster week of research
22 July 2024
Staff and students at Ludwig Oxford and the Institute of Developmental and Regenerative Medicine put on lectures, panel sessions, lab workshops and more for 6th form students with a keen interest in scientific research.
Ludwig Oxford at 2024 AACR
17 April 2024
Ludwig Oxford staff and students alike share their research in San Diego at the 2024 AACR Annual Meeting
International Women's Day within Ludwig Oxford
8 March 2024
The 8th March annually celebrates Women's achievements and we are delighted to celebrate the women researchers, students and staff within Ludwig Oxford
New DPhil studentships in Cancer Science available for 2024 intake
30 October 2023
Ludwig Oxford supervised DPhil studentships in Cancer Science are now being advertised for the 2024 intake
Ludwig Oxford clinical trial shows Immunochemotherapy outcomes predicted by tumour monocyte content
11 July 2023
An analysis of samples obtained from a uniquely designed window-of-opportunity clinical trial (LUD2015-005) has shown that high tumour monocyte content (TMC) is an unexpected predictor of greater overall survival in inoperable oesophageal adenocarcinoma (OAC) patients.
Hypertension treatment drugs may play a role in boosting clinical immunotherapy
8 June 2023
Team from the Van den Eynde group have discovered that some molecules previously used to treat hypertension might also help the immune system to better fight cancer cells
Ludwig Oxford research wins Journal for ImmunoTherapy of Cancer’s best basic tumour immunology paper of 2022
15 November 2022
A paper on a therapeutic cancer vaccine from the Van den Eynde lab was singled out for this award celebrating excellence in scientific research.
Mechanistic insights into the ZBP1 inflammatory response
21 October 2022
A collaborative study, led by former Ludwig Oxford group leader Professor Mads Gyrd-Hansen, sheds light on the ZBP1-induced signalling pathway, a pathway which contributes to the viral immune response, including to SARS-CoV-2
Cancer at Oxford
29 September 2022
Read about how Oxford's experts - including Ludwig Oxford scientists - are leading the way in cancer prevention, detection and treatment as part of the University's Cancer at Oxford series
Ludwig Oxford retreat 2022 – a recap
15 July 2022
- Barnes
- Boccellato
- Byrne
- Constantinescu
- De Val
- Goding
- Kriaucionis
- Lu
- Mehdipour
- Moura Alves
- Ratcliffe
- Schuster-Böckler
- Shi
- Song
- Van den Eynde
On 13-14th June 2022, the Oxford Branch of the Ludwig Institute for Cancer Research held their annual retreat to discuss key scientific advances within the Branch and beyond.
First patient dosed in phase I/IIa trial of lung cancer immunotherapy vaccine
18 January 2022
A novel immunotherapeutic called VTP-600, based on Ludwig Oxford’s Benoit Van den Eynde’s preclinical research, is being tested in patients for the first time.
Vaccine for treating cancer made possible using Oxford COVID vaccine technology
3 September 2021
A new publication from Benoit Van den Eynde's group has shown that a viral vector cancer vaccine generates effective anti-tumour immune responses and, in combination with immunotherapy, decreases tumour size and increases survival rates in mouse models.
UNIQ summer school 2021
22 July 2021
Three Ludwig Oxford volunteers participate at the 2021 Oncology UNIQ summer school
Clinical trial for therapeutic cancer vaccine
18 December 2019
Research from Benoit Van den Eynde’s laboratory forms the basis of a Phase I/IIa clinical trial.